The use of primary systemic chemotherapy for the treatment of 'operable' breast cancer evolved from the need to improve the outlook of patients with disease that is locally advanced but apparently without metastases. Trials are now showing that this can also be a worthwhile approach to the treatment of primary breast cancer in the elderly.